eFoodSafety Featured in Knobias’ smallcap ClipReport

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF, www.efoodsafety.com), a researcher and developer of nutraceutical and whole food products, was recently featured in the smallcap ClipReport, a newsletter published by Knobias, a financial information company that specializes in small-cap stocks.

The article, entitled “EFSF Provides Update on Citroxin and Other Promising Products,” highlights eFoodSafety’s Citroxin and the testing that is currently being done in Thailand on a chick embryo model to determine, “the product’s ability to safely and effectively eradicate the most virulent form of the bird flu, the H5N1 virus.” The report also describes eFoodSafety Director Timothy Matula’s recent attendance at the Bangkok International Conference on Avian Influenza, as well as Citroxin’s 100% “kill rate” for the “big six” bacterial health threats.

The piece goes on to discuss the rest of eFoodSafety’s line of existing products, as well as products in the company’s pipeline. Detailed in the report is Cinnergen™, a whole food supplement for normalizing blood sugar; Talsyn™ Scar Cream, a topical cream used for the management of scars; and the ImmuneBoost Bar™, an energy bar that enhances overall immune function. In the article Matula states, “our mission is to develop innovative products and technologies that improve health conditions and enhance the quality of food worldwide.”

“We are pleased to be featured in Knobias’ smallcap ClipReport, a well-respected source of information on emerging small-cap stocks,” says Patricia Gruden, CEO of eFoodSafety. “This is a very exciting time for the company as we will soon launch our direct-response campaigns for Cinnergen, Cinnechol™, and NumaDerm™. Inclusion in the Knobias smallcap ClipReport helps us to gain visibility with members of the small-cap investment community.”

For additional information regarding the smallcap ClipReport, or to review the report in full, please visit www.knobias.com.

About smallcap ClipReport

This daily newsletter is the market’s most objective and comprehensive source for small- and micro-cap action. No one covers small-caps like Knobias. This newsletter provides a condensed, overnight snapshot of select Knobias small-cap content being distributed to its real-time Wall Street customers each day. ClipReport content is generally focused only on those stocks below $500M in marketcap. Stocks in the following sectors are also generally excluded: Banks, Closed-End Funds, ETFs, and Utilities.

About eFoodSafety.com

eFoodSafety.com, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The company’s Cinnergen™ is a clinically-researched, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, is available for sale at (www.cinnergen.com) and through national retailers; its Cinnechol™ is a multi-faceted nutritional supplement specifically designed to naturally promote reduction in total cholesterol levels without causing any side effects, as well as overall cardiovascular health. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.

The company’s iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system. The product contains Citroxin O2™, eFoodSafety’s proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in four delicious flavors: chocolate, oatmeal-raisin, chocolate mint and peanut butter and can be purchased at www.immuneboost.com.

The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the owner of the Talsyn™-CI/bid Scar Cream, a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.

Please visit the company’s website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.